<P>Recent strategies for treating CML patients have focused on investigating new combinations of tyrosine kinase inhibitors (TKIs) as well as identifying novel translational research agents that can eradicate CML leukemia‐initiating cells...
http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
https://www.riss.kr/link?id=A107501224
Naka, Kazuhito ; Ishihara, Kaori ; Jomen, Yoshie ; Jin, Cheng Hua ; Kim, Dong‐ ; Hyun ; Gu, Yoon‐ ; Kang ; Jeong, Eun‐ ; Sook ; Li, Shaoguang ; Krause, Daniela S. ; Kim, Dong‐ ; Wook ; Bae, Eunjin ; Takihara, Yoshihiro ; Hirao, Atsushi ; Oshima, Hiroko ; Oshima, Masanobu ; Ooshima, Akira ; Sheen, Yhun Yhong ; Kim, Seong‐ ; Jin ; Kim, Dae‐ ; Kee
2016
-
SCI,SCIE,SCOPUS
학술저널
140-148(9쪽)
0
상세조회0
다운로드다국어 초록 (Multilingual Abstract)
<P>Recent strategies for treating CML patients have focused on investigating new combinations of tyrosine kinase inhibitors (TKIs) as well as identifying novel translational research agents that can eradicate CML leukemia‐initiating cells...
<P>Recent strategies for treating CML patients have focused on investigating new combinations of tyrosine kinase inhibitors (TKIs) as well as identifying novel translational research agents that can eradicate CML leukemia‐initiating cells (CML‐LICs). However, little is known about the therapeutic benefits such CML‐LIC targeting therapies might bring to CML patients. In this study, we investigated the therapeutic potential of EW‐7197, an orally bioavailable transforming growth factor‐β signaling inhibitor which has recently been approved as an Investigational New Drug (NIH, USA), to suppress CML‐LICs <I>in vivo</I>. Compared to TKI treatment alone, administration of TKI plus EW‐7197 to CML‐affected mice significantly delayed disease relapse and prolonged survival. Notably, combined treatment with EW‐7197 plus TKI was effective in eliminating CML‐LICs even if they expressed the TKI‐resistant T315I mutant <I>BCR‐ABL1</I> oncogene. Collectively, these results indicate that EW‐7197 may be a promising candidate for a new therapeutic that can greatly benefit CML patients by working in combination with TKIs to eradicate CML‐LICs.</P>